Matches in SemOpenAlex for { <https://semopenalex.org/work/W2006603022> ?p ?o ?g. }
- W2006603022 endingPage "744" @default.
- W2006603022 startingPage "739" @default.
- W2006603022 abstract "Objectives The objectives of this study were to evaluate the local oral defense mechanisms during the course of leukemia, and to define the correlation between the activity of salivary antibacterial factors and the oral clinical findings. Study design A total of 44 children with newly diagnosed acute leukemia participated in the study. The control group consisted of 23 healthy children. The examination took place at the time of the diagnosis, and during and at the end of the chemotherapy treatment course. During the collection of resting mixed saliva samples the salivary flow rate was measured. In the saliva's supernatant the following parameters were determined: total protein, peroxidase, myeloperoxidase, lysozyme, lactoferrin, and secretory immunoglobulin A. Results The introduction of chemotherapy caused a slight decrease of salivary secretion rate (P < .05), as well as the decrease of S-IgA concentration (P < .01), which remained at the same level after the end of chemotherapy (P < .001). Patients with aplasia had decreased levels of peroxidase (P = .014) and myeloperoxidase (P = .013). Patients with oral mucositis presented with lower myeloperoxidase (P = .026) and peroxidase (P = .003) activity levels as well as the drop of S-IgA (P = .000) concentration compared with subjects with no mucositis. Conclusions Antileukemic treatment contributes to the compromise of salivary defense mechanisms, therefore it is reasonable to support pharmacologically the saliva's antibacterial potential of leukemic patients to impede the development of local infection. The objectives of this study were to evaluate the local oral defense mechanisms during the course of leukemia, and to define the correlation between the activity of salivary antibacterial factors and the oral clinical findings. A total of 44 children with newly diagnosed acute leukemia participated in the study. The control group consisted of 23 healthy children. The examination took place at the time of the diagnosis, and during and at the end of the chemotherapy treatment course. During the collection of resting mixed saliva samples the salivary flow rate was measured. In the saliva's supernatant the following parameters were determined: total protein, peroxidase, myeloperoxidase, lysozyme, lactoferrin, and secretory immunoglobulin A. The introduction of chemotherapy caused a slight decrease of salivary secretion rate (P < .05), as well as the decrease of S-IgA concentration (P < .01), which remained at the same level after the end of chemotherapy (P < .001). Patients with aplasia had decreased levels of peroxidase (P = .014) and myeloperoxidase (P = .013). Patients with oral mucositis presented with lower myeloperoxidase (P = .026) and peroxidase (P = .003) activity levels as well as the drop of S-IgA (P = .000) concentration compared with subjects with no mucositis. Antileukemic treatment contributes to the compromise of salivary defense mechanisms, therefore it is reasonable to support pharmacologically the saliva's antibacterial potential of leukemic patients to impede the development of local infection." @default.
- W2006603022 created "2016-06-24" @default.
- W2006603022 creator A5023243734 @default.
- W2006603022 creator A5025612296 @default.
- W2006603022 creator A5028311781 @default.
- W2006603022 creator A5029088578 @default.
- W2006603022 creator A5070099404 @default.
- W2006603022 date "2008-06-01" @default.
- W2006603022 modified "2023-10-17" @default.
- W2006603022 title "Antibacterial potential of saliva in children with leukemia" @default.
- W2006603022 cites W1656770909 @default.
- W2006603022 cites W1967195838 @default.
- W2006603022 cites W1983122202 @default.
- W2006603022 cites W1994379637 @default.
- W2006603022 cites W1994855654 @default.
- W2006603022 cites W1997191890 @default.
- W2006603022 cites W2015272421 @default.
- W2006603022 cites W2020512504 @default.
- W2006603022 cites W2036187438 @default.
- W2006603022 cites W2039486219 @default.
- W2006603022 cites W2042133388 @default.
- W2006603022 cites W2043093140 @default.
- W2006603022 cites W2045819835 @default.
- W2006603022 cites W2048732102 @default.
- W2006603022 cites W2051754751 @default.
- W2006603022 cites W2063962064 @default.
- W2006603022 cites W2072388521 @default.
- W2006603022 cites W2072778101 @default.
- W2006603022 cites W2082700596 @default.
- W2006603022 cites W2102964268 @default.
- W2006603022 cites W2108228710 @default.
- W2006603022 cites W2119053408 @default.
- W2006603022 cites W2120547848 @default.
- W2006603022 cites W2162701168 @default.
- W2006603022 cites W2171784054 @default.
- W2006603022 cites W2400477896 @default.
- W2006603022 cites W4232534952 @default.
- W2006603022 doi "https://doi.org/10.1016/j.tripleo.2007.10.010" @default.
- W2006603022 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18329914" @default.
- W2006603022 hasPublicationYear "2008" @default.
- W2006603022 type Work @default.
- W2006603022 sameAs 2006603022 @default.
- W2006603022 citedByCount "27" @default.
- W2006603022 countsByYear W20066030222012 @default.
- W2006603022 countsByYear W20066030222013 @default.
- W2006603022 countsByYear W20066030222014 @default.
- W2006603022 countsByYear W20066030222015 @default.
- W2006603022 countsByYear W20066030222016 @default.
- W2006603022 countsByYear W20066030222017 @default.
- W2006603022 countsByYear W20066030222019 @default.
- W2006603022 countsByYear W20066030222020 @default.
- W2006603022 countsByYear W20066030222021 @default.
- W2006603022 countsByYear W20066030222022 @default.
- W2006603022 countsByYear W20066030222023 @default.
- W2006603022 crossrefType "journal-article" @default.
- W2006603022 hasAuthorship W2006603022A5023243734 @default.
- W2006603022 hasAuthorship W2006603022A5025612296 @default.
- W2006603022 hasAuthorship W2006603022A5028311781 @default.
- W2006603022 hasAuthorship W2006603022A5029088578 @default.
- W2006603022 hasAuthorship W2006603022A5070099404 @default.
- W2006603022 hasConcept C126322002 @default.
- W2006603022 hasConcept C203014093 @default.
- W2006603022 hasConcept C203565725 @default.
- W2006603022 hasConcept C2776694085 @default.
- W2006603022 hasConcept C2776863199 @default.
- W2006603022 hasConcept C2776914184 @default.
- W2006603022 hasConcept C2776966407 @default.
- W2006603022 hasConcept C2778461978 @default.
- W2006603022 hasConcept C2778496288 @default.
- W2006603022 hasConcept C2779170986 @default.
- W2006603022 hasConcept C504460877 @default.
- W2006603022 hasConcept C55493867 @default.
- W2006603022 hasConcept C71924100 @default.
- W2006603022 hasConcept C86803240 @default.
- W2006603022 hasConcept C90924648 @default.
- W2006603022 hasConceptScore W2006603022C126322002 @default.
- W2006603022 hasConceptScore W2006603022C203014093 @default.
- W2006603022 hasConceptScore W2006603022C203565725 @default.
- W2006603022 hasConceptScore W2006603022C2776694085 @default.
- W2006603022 hasConceptScore W2006603022C2776863199 @default.
- W2006603022 hasConceptScore W2006603022C2776914184 @default.
- W2006603022 hasConceptScore W2006603022C2776966407 @default.
- W2006603022 hasConceptScore W2006603022C2778461978 @default.
- W2006603022 hasConceptScore W2006603022C2778496288 @default.
- W2006603022 hasConceptScore W2006603022C2779170986 @default.
- W2006603022 hasConceptScore W2006603022C504460877 @default.
- W2006603022 hasConceptScore W2006603022C55493867 @default.
- W2006603022 hasConceptScore W2006603022C71924100 @default.
- W2006603022 hasConceptScore W2006603022C86803240 @default.
- W2006603022 hasConceptScore W2006603022C90924648 @default.
- W2006603022 hasIssue "6" @default.
- W2006603022 hasLocation W20066030221 @default.
- W2006603022 hasLocation W20066030222 @default.
- W2006603022 hasOpenAccess W2006603022 @default.
- W2006603022 hasPrimaryLocation W20066030221 @default.
- W2006603022 hasRelatedWork W1538818159 @default.
- W2006603022 hasRelatedWork W1586040773 @default.
- W2006603022 hasRelatedWork W1965721198 @default.